Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer

Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer

BackgroundProgrammed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune-related adverse events (irAEs) are inevitable in patients with liver cancer. Although the incidence of severe irAEs is low, but can result in fatal consequences. To date, only a few commonly used clinical biomark...

Full description

Bibliographic Details
Main Authors: Yingying Yu, Siyu Wang, Nan Su, Shida Pan, Bo Tu, Jinfang Zhao, Yingjuan Shen, Qin Qiu, Xiaomeng Liu, Junqing Luan, Fu-Sheng Wang, Fanping Meng, Ming Shi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
liver cancer
immune related adverse events
C-reactive protein
interleukin-6
lymphocyte subsets
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.906824/full

Similar Items

Similar Items